Suppr超能文献

非甾体抗炎药治疗下腰痛。

Nonsteroidal anti-inflammatory drugs in the treatment of low back pain.

机构信息

Department of Community Health and Family Medicine, University of Florida, Gainesville, FL, USA.

出版信息

J Pain Res. 2012;5:579-90. doi: 10.2147/JPR.S6775. Epub 2012 Nov 28.

Abstract

Low back pain (LBP) is amongst the top ten most common conditions presenting to primary care clinicians in the ambulatory setting. Further, it accounts for a significant amount of health care expenditure; indeed, over one third of all disability dollars spent in the United States is attributable to low back pain. In most cases, acute low back pain is a self-limiting disease. There are many evidence-based guidelines for the management of LBP. The most common risk factor for development of LBP is previous LBP, heavy physical work, and psychosocial risk factors. Management of LBP includes identification of red flags, exclusion of specific secondary causes, and comprehensive musculoskeletal/neurological examination of the lower extremities. In uncomplicated LBP, imaging is unnecessary unless symptoms become protracted. Reassurance that LBP will likely resolve and advice to maintain an active lifestyle despite LBP are the cornerstones of management. Medications are provided not because they change the natural history of the disorder, but rather because they enhance the ability of the patient to become more active, and in some cases, to sleep better. The most commonly prescribed medications include nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants. Although NSAIDs are a chemically diverse class, their similarities, efficacy, tolerability, and adverse effect profile have more similarities than differences. The most common side effects of NSAIDs are gastrointestinal. Agents with cyclo-oxygenase 2 selectivity are associated with reduced gastrointestinal bleeding, but problematic increases in adverse cardiovascular outcomes continue to spark concern. Fortunately, short-term use of NSAIDs for LBP is generally both safe and effective. This review will focus on the role of NSAIDs in the management of LBP.

摘要

下背痛(LBP)是在门诊环境中向初级保健临床医生就诊的十大最常见病症之一。此外,它还导致了大量的医疗保健支出;事实上,美国花费的所有残疾美元中超过三分之一归因于下背痛。在大多数情况下,急性下背痛是一种自限性疾病。有许多针对 LBP 管理的循证指南。LBP 发展最常见的危险因素是先前的 LBP、重体力工作和心理社会危险因素。LBP 的管理包括识别危险信号、排除特定的继发性原因以及对下肢进行全面的肌肉骨骼/神经检查。在不复杂的 LBP 中,除非症状持续存在,否则不需要进行影像学检查。向患者保证 LBP 可能会缓解,并建议他们即使有 LBP 也要保持积极的生活方式,这是管理的基石。提供药物不是因为它们改变了疾病的自然病程,而是因为它们增强了患者变得更加活跃的能力,在某些情况下,还能改善睡眠。最常开的药物包括非甾体抗炎药(NSAIDs)和肌肉松弛剂。尽管 NSAIDs 是一类化学性质多样的药物,但它们的相似性、疗效、耐受性和不良影响特征比差异更多。NSAIDs 最常见的副作用是胃肠道。具有环氧化酶 2 选择性的药物与减少胃肠道出血有关,但有问题的不良心血管结局增加仍继续引起关注。幸运的是,短期使用 NSAIDs 治疗 LBP 通常既安全又有效。本综述将重点讨论 NSAIDs 在 LBP 管理中的作用。

相似文献

1
Nonsteroidal anti-inflammatory drugs in the treatment of low back pain.
J Pain Res. 2012;5:579-90. doi: 10.2147/JPR.S6775. Epub 2012 Nov 28.
3
Pharmacologic management of chronic low back pain: synthesis of the evidence.
Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S131-43. doi: 10.1097/BRS.0b013e31822f178f.
5
What a pain in the … back: a review of current treatment options with a focus on naproxen sodium.
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.
7
Strategies for prevention and management of musculoskeletal conditions. Low back pain (non-specific).
Best Pract Res Clin Rheumatol. 2007 Feb;21(1):77-91. doi: 10.1016/j.berh.2006.08.004.
8
Advice for the management of low back pain: a systematic review of randomised controlled trials.
Man Ther. 2007 Nov;12(4):310-27. doi: 10.1016/j.math.2006.12.009. Epub 2007 Mar 28.
10

引用本文的文献

2
Current Therapeutic Strategies of Intervertebral Disc Regenerative Medicine.
Mol Diagn Ther. 2024 Nov;28(6):745-775. doi: 10.1007/s40291-024-00729-7. Epub 2024 Aug 19.
4
Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients.
Cureus. 2023 Oct 10;15(10):e46790. doi: 10.7759/cureus.46790. eCollection 2023 Oct.
6
Clinical and economic burden of low back pain in low- and middle-income countries: a systematic review.
BMJ Open. 2023 Apr 25;13(4):e064119. doi: 10.1136/bmjopen-2022-064119.
8
Obesity and the Receipt of Prescription Pain Medications in the US.
J Gen Intern Med. 2021 Sep;36(9):2631-2638. doi: 10.1007/s11606-020-06581-9. Epub 2021 Feb 8.
9
Investigating the Effect of Melissa Officinalis on After-Pains: A Randomized Single-Blind Clinical Trial.
J Caring Sci. 2019 Sep 1;8(3):129-138. doi: 10.15171/jcs.2019.019. eCollection 2019 Sep.

本文引用的文献

1
An updated overview of clinical guidelines for the management of non-specific low back pain in primary care.
Eur Spine J. 2010 Dec;19(12):2075-94. doi: 10.1007/s00586-010-1502-y. Epub 2010 Jul 3.
2
Current and emerging treatments for mild/moderate acute ambulatory pain.
Am J Ther. 2008 Nov-Dec;15 Suppl 10:S12-6. doi: 10.1097/MJT.0b013e31818be66f.
3
A 50-year-old man with chronic low back pain.
JAMA. 2008 May 7;299(17):2066-77. doi: 10.1001/jama.299.13.jrr80002. Epub 2008 Apr 1.
4
Non-steroidal anti-inflammatory drugs for low back pain.
Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD000396. doi: 10.1002/14651858.CD000396.pub3.
5
Epidemiology and risk factors for spine pain.
Neurol Clin. 2007 May;25(2):353-71. doi: 10.1016/j.ncl.2007.01.004.
6
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
JAMA. 2006 Oct 4;296(13):1619-32. doi: 10.1001/jama.296.13.jrv60015. Epub 2006 Sep 12.
7
Chronic back pain among the elderly: prevalence, associations, and predictors.
Spine (Phila Pa 1976). 2006 Apr 1;31(7):E203-7. doi: 10.1097/01.brs.0000206367.57918.3c.
8
Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care.
Eur Spine J. 2006 Mar;15 Suppl 2(Suppl 2):S169-91. doi: 10.1007/s00586-006-1071-2.
9
Current state of therapy for pain and inflammation.
Arthritis Res Ther. 2005;7 Suppl 4(Suppl 4):S1-6. doi: 10.1186/ar1792. Epub 2005 Sep 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验